Disclosed herein are a chromium compound represented by Formula 1a or 1c and a catalyst system including the same, exhibiting superior catalytic activity in an olefin trimerization reaction:
[{CH.sub.3(CH.sub.2).sub.3CH(CH.sub.2CH.sub.3)CO.sub.2}.sub.2Cr(OH)][Formula 1a]
[{CH.sub.3(CH.sub.2).sub.3CH(CH.sub.2CH.sub.3)CO.sub.2}.sub.2Cr(OH)].sub.4.2H.sub.2O.[Formula 1c]

The present invention relates to a catalyst system comprising a transition metal compound on a solid carrier which is a surface-reacted calcium carbonate. The invention further relates to a method for manufacturing said catalyst system and to its use in heterogeneous catalysis.

The present invention discloses a phosphine free cobalt based catalyst of formula (I) and a process for preparation thereof. The present invention further discloses a process for the synthesis of aromatic heterocyclic compounds of formula (II) and pyrazine derivative using the phosphine free cobalt based catalyst of formula (I).

An oxidative homocoupling method of synthesizing certain 2,2-bithiophenes from thiophenes using oxygen as the terminal oxidant is disclosed. In non-limiting examples, the method uses oxygen along with a catalytic system that includes palladium, an assistive ligand, and a non-palladium metal additive to catalyze one of the following reactions: ##STR00001## Associated catalytic systems and compositions are also disclosed.

Disclosed are processes and intermediates for the preparation of compound (X), which is currently being investigated for the treatment of prostate cancer.

##STR00001##

The present invention relates, in part, to methods for depolymerizing a polymer, in which the method includes use of a magnetic catalyst. The magnetic catalyst can include, e.g., a ore-shell particle, such as a particle having a magnetic core and a shell including a metal-organic framework.

A process for the selective removal of a component from a liquid phase and subsequently returning the component to a liquid phase is disclosed. A novel compound of formula I [SUP]-[[L]-[G]].sub.a (I) in which L is a linking group, G is an aryl group having a leaving group LG selected from Cl, Br, I, sulfonate such as triflate, a diazo group, a nitrile, an ester and an alkoxy group and substituent Q is selected from H, NR.sub.2, OR, CO.sub.2R, F, Cl, NO.sub.2 CN and SUP is a support having a plurality of groups -[L]-[G] bound to the support is contacted with the liquid phase to bind the component to the compound I thereby forming a captured component which is separated from and may be returned to the liquid phase. The compound I is especially useful in binding homogeneous catalysts to remove it from a reaction medium and selectively returning the catalyst to the reaction medium at a later stage. The compound is particularly useful for cross-coupling reactions, for example in Suzuki reactions.

Disclosed are processes and intermediates for the preparation of compound (X), which is currently being investigated for the treatment of prostate cancer. ##STR00001##

A production method for a catalyst, in which a catalyst that is a metallocene compound can be produced with high purity and high yield using a ligand of a specific structure containing a fluorene skeleton. The catalyst is produced by a method including a step (I) in which a ligand of a specific structure containing a fluorene skeleton is reacted with a specific amount of an organic lithium compound of a specific structure; a step (II) in which the product of step (I) is reacted with one or more of Mg compounds of a predetermined structure, Zn compounds of a predetermined structure and Al compounds of a predetermined structure; and a step (III) in which the product of step (II) is reacted with at least 1 molar equivalent, with respect to the ligand, of a Ti compound, a Zr compound or an Hf compound, the compound having a halogen atom or the like.

The present disclosure provides a method for efficiently producing and providing compounds having a spirooxindole skeleton, for example compounds having a spirooxindole skeleton and having antitumor activity that inhibit the interaction between Mdm2 protein and p53 protein, or intermediates thereof, using an asymmetric catalyst. Compounds having optically active tricyclic dispiroindole skeletons are obtained through catalytic asymmetric 1,3-dipolar cycloaddition reaction using ketimine as a reaction substrate and using a chiral ligand and a Lewis acid.